Lindsell, Christopher J. http://orcid.org/0000-0002-3297-2811
McGlothlin, Anna
Nwosu, Samuel
Rice, Todd W.
Hall, Alex
Bernard, Gordon R.
Busse, Laurence W.
Ely, E. Wesley
Fowler, Alpha A.
Gaieski, David F.
Hinson, Jeremiah S.
Hooper, Michael H.
Jackson, James C.
Kelen, Gabor D.
Levine, Mark
Martin, Greg S.
Rothman, Richard E.
Sevransky, Jonathan E.
Viele, Kert
Wright, David W.
Hager, David N.
Funding for this research was provided by:
The Marcus Foundation
Nova Biomedical
Article History
Received: 19 July 2019
Accepted: 9 October 2019
First Online: 4 December 2019
Ethics approval and consent to participate
: The study was approved by a central Institutional Review Board (IRB; Johns Hopkins University IRB protocol number IRB00164053). Each site’s local IRB will approve the Informed Consent Document for local use and will formally rely on this central approval before enrollment may proceed at that site. This study is registered with ClinicalTrials.gov as NCT03509350.
: CJL reports funding for the VICTAS trial to his institution from the Marcus Foundation, and is named as co-inventor on patents related to risk stratification in septic shock. AM and KV are salaried employees of Berry Consultants, which is under contract with Emory University to support the design work and execution of the VICTAS trial. AH reports funding for the VICTAS trial to his institution from the Marcus Foundation as well as grants from the National Institutes of Health (NIH), Cerenovus, and the NICO Corporation. SN, GRB, DNH, JSH, TWR, and RER report funding for the VICTAS trial to their institutions from the Marcus Foundation. EWE reports funding for the VICTAS trial to his institution from the Marcus Foundation and has received honoraria from Pfizer, Orion, and Masimo for continuing medical education activities (but no speakers’ bureaus or stocks etc.). ML is supported by the Intramural Research Program, NIDDK, NIH DK053212–12: Ascorbic acid as a pharmacologic agent in disease treatment. GSM reports grants for the VICTAS trial to his institution from the Marcus Foundation as well as grants from NIH, Biomedical Advanced Research and Development Authority (BARDA) and Bristol-Myers Squibb to his institution. JES reports grants for the VICTAS trial to his institution from the Marcus Foundation, funding from BARDA, and a stipend from the Society of Critical Care Medicine to support his editorial position for the journal <i>Critical Care Medicine</i>. DWW reports the grant for the VICTAS trial to his institution from the Marcus Foundation as well as grants from the NIH, the National Highway Transportation Safety Administration, the Department of Defense, NICO Corporation, and the Centers for Disease Control and Prevention. All remaining authors declare that they have no competing interests.